Pandorum Technologies secured 18 million dollars in Series B funding to advance its 3D bioprinting a...

Pandorum Technologies secured 18 million dollars in Series B funding to advance its 3D bioprinting and regenerative medicine pipeline. This capital supports the clinical trials of Kuragenx, an FDA-designated liquid cornea therapy. For the AM industry, this signals a critical transition from lab-scale scaffolds to functional, clinical-grade tissue manufacturing. Global partnerships with AGC Biologics and Nucelion will scale this bio-fabrication infrastructure for international markets. 🚀 #3DBioprinting #Biotech #Funding